ArticleFrontiers in medicine2026
Clinical characteristics, genotype-phenotype correlation, and prognostic follow-up of 48 Chinese children with hereditary spherocytosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This retrospective single-center observational study aimed to characterize clinical phenotypes and pathogenic mutation spectra in Chinese children with hereditary spherocytosis (HS), analyze genotype-phenotype correlations. Methods: Clinical and genetic data of 48 pediatric HS patients admitted to the First Affiliated Hospital of Naval Medical University from May 2016 to March 2024 were retrospectively analyzed. Clinical indices were compared across subgroups stratified by mutant genes and variant types. Forty patients were followed up via telephone to record post-discharge symptoms, therapies and complications such as cholelithiasis. Results: Forty-eight pathogenic variants were confirmed, including 13 novel mutations. SPTB (43.75%) and ANK1 (37.5%) predominated, and 28 patients had positive family histories. Moderate-severe anemia patients presented earlier diagnosis, more transfusions and lower MCHC. ANK1 variants correlated with higher reticulocyte levels and more transfusion dependence; splicing variants were linked to elevated reticulocytes and higher splenomegaly rates, while missense variants yielded milder manifestations. Among 40 followed patients, 12 received splenectomy with resolved hemolysis, no transfusions, improved exercise tolerance and unimpaired growth. No children had a height below P3, and growth profiles were similar between splenectomized and non-splenectomized patients. Conclusion: This is the largest Chinese single-center cohort with the longest reported follow-up of pediatric HS, featuring distinct local mutational profiles. This study enriches the Chinese HS mutation spectrum and guides clinical management, genetic counseling and future gene therapy research for pediatric HS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.